{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:11:51Z","timestamp":1788966711533,"version":"build-2803163510"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,6,15]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In searching for an optimal induction regimen, we conducted two separate randomized trials of 38 living donor and 90 deceased donor adult, primary kidney transplant recipients comparing antithymocyte globulin (Thymoglobulin) (group A, N=43) versus alemtuzumab (group B, N=43) versus daclizumab (group C, N=42), using exactly the same three treatment arms in each trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>For the purpose of maximizing statistical power, results from the two randomized trials were combined. Groups A and C received standard maintenance dosing with tacrolimus (TAC), mycophenolate mofetil (MMF), and corticosteroids. Because of intense lymphodepletion expected with alemtuzumab use (and hoped-for achievement of a truer immunoregulatory state), group B received lower TAC and MMF dosing and corticosteroid avoidance. Long-term target TAC trough level and MMF dosing were 5 to 7 ng\/mL and 1,000 mg b.i.d. in groups A and C; 4 to 6 ng\/mL and 500 mg b.i.d. in group B.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      With median follow-up of 95 months, biopsy-proven cute rejection incidence was similar in the three groups (8\/43, 14\/43, and 12\/42,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.34), but biopsy-proven chronic allograft injury incidence was significantly higher in group B (19\/43) in comparison with groups A (9\/43) and C (7\/42) combined (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.0008). Mean calculated creatinine clearance was significantly lower in group B versus the average of groups A and C means throughout 60 months posttransplant (62.9\u00b14.2 vs. 83.6\u00b16.9 and 79.8\u00b15.9 at 60 months,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.01), and death-censored graft failure was significantly higher in group B (13\/43) versus groups A (5\/43) and C (5\/42) combined (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.009). Total infection and new-onset diabetes after transplant rates were not significantly different. Ad hoc analysis suggested that the inferior results in group B were specifically a result of reduced dosing and greater withholding of TAC and MMF occurring in that group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Long-term results clearly indicate inferior clinical outcomes in group B.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/01.tp.0000441089.39840.66","type":"journal-article","created":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T17:02:29Z","timestamp":1391014949000},"page":"1128-1138","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":38,"title":["Randomized Trial of Three Induction Antibodies in Kidney Transplantation"],"prefix":"10.1097","volume":"97","author":[{"given":"Gaetano","family":"Ciancio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Gaynor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giselle","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Sageshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Mattiazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Kupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissett","family":"Tueros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Vianna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George W.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20260909","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM199801153380304","article-title":"Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.","volume":"338","author":"Vincenti","year":"1998","journal-title":"N Engl J Med"},{"key":"R2-10-20260909","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00007890-199901150-00019","article-title":"Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.","volume":"67","author":"Nashan","year":"1999","journal-title":"Transplantation"},{"key":"R3-10-20260909","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1097\/00007890-200204150-00015","article-title":"Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.","volume":"73","author":"Ciancio","year":"2002","journal-title":"Transplantation"},{"key":"R4-10-20260909","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00007890-199807150-00005","article-title":"Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes following renal transplant.","volume":"66","author":"Gaber","year":"1998","journal-title":"Transplantation"},{"key":"R5-10-20260909","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/01.TP.0000081042.67285.91","article-title":"A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients.","volume":"76","author":"Goggins","year":"2003","journal-title":"Transplantation"},{"key":"R6-10-20260909","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/01.sla.0000137140.79206.d0","article-title":"Long-term immunosuppression, without maintenance prednisone, after kidney transplantation.","volume":"240","author":"Matas","year":"2004","journal-title":"Ann Surg"},{"key":"R7-10-20260909","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1034\/j.1600-6143.2003.00120.x","article-title":"Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.","volume":"3","author":"Knechtle","year":"2003","journal-title":"Am J Transplant"},{"key":"R8-10-20260909","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/01.TP.0000128625.29654.EB","article-title":"The use of Campath-1H as induction therapy in renal transplantation: preliminary results.","volume":"78","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"key":"R9-10-20260909","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/S0140-6736(05)77739-4","article-title":"Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients.","volume":"351","author":"Calne","year":"1998","journal-title":"Lancet"},{"key":"R10-10-20260909","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/01.tp.0000165847.05787.08","article-title":"A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.","volume":"80","author":"Ciancio","year":"2005","journal-title":"Transplantation"},{"key":"R11-10-20260909","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1399-0012.2007.00774.x","article-title":"A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow up.","volume":"22","author":"Ciancio","year":"2008","journal-title":"Clin Transplant"},{"key":"R12-10-20260909","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1016\/j.transproceed.2010.08.045","article-title":"Randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in living donor renal transplantation.","volume":"42","author":"Ciancio","year":"2010","journal-title":"Transplant Proc"},{"key":"R13-10-20260909","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/TP.0b013e31822805d7","article-title":"Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal.","volume":"92","author":"Heilman","year":"2011","journal-title":"Transplantation"},{"key":"R14-10-20260909","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/TP.0b013e3182394cb3","article-title":"Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal.","volume":"93","author":"Heilman","year":"2012","journal-title":"Transplantation"},{"key":"R15-10-20260909","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1681\/ASN.2010020181","article-title":"The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase.","volume":"21","author":"DellOglio","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R16-10-20260909","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1034\/j.1600-6143.2003.00005.x","article-title":"Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil.","volume":"3","author":"Vincenti","year":"2003","journal-title":"Am J Transplant"},{"key":"R17-10-20260909","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1399-0012.2004.00298.x","article-title":"Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies.","volume":"19","author":"Kumar","year":"2005","journal-title":"Clin Transplant"},{"key":"R18-10-20260909","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.surg.2004.10.013","article-title":"Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety.","volume":"137","author":"Laftavi","year":"2005","journal-title":"Surgery"},{"key":"R19-10-20260909","first-page":"673","article-title":"Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study.","volume":"2","author":"Nematalla","year":"2007","journal-title":"Exp Clin Transplant"},{"key":"R20-10-20260909","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/SLA.0b013e318187d1da","article-title":"for the Astellas Corticosteroid Withdrawal Study Group. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (day 7) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.","volume":"248","author":"Woodle","year":"2008","journal-title":"Ann Surg"},{"key":"R21-10-20260909","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1600-6143.2007.02057.x","article-title":"on behalf of the FREEDOM Study Group. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients.","volume":"8","author":"Vincenti","year":"2008","journal-title":"Am J Transplant"},{"key":"R22-10-20260909","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/ndt\/gfm621","article-title":"A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine.","volume":"23","author":"Montagnino","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R23-10-20260909","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/01.TP.0000071362.99021.D9","article-title":"Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Campath-1H).","volume":"76","author":"Kirk","year":"2003","journal-title":"Transplantation"},{"key":"R24-10-20260909","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/01.tp.0000174341.49741.8f","article-title":"Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin.","volume":"80","author":"Kirk","year":"2005","journal-title":"Transplantation"},{"key":"R25-10-20260909","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1600-6143.2005.00759.x","article-title":"Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion.","volume":"5","author":"Pearl","year":"2005","journal-title":"Am J Transplant"},{"key":"R26-10-20260909","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/01.tp.0000166921.14670.33","article-title":"Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation.","volume":"80","author":"Vathsala","year":"2005","journal-title":"Transplantation"},{"key":"R27-10-20260909","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/01.tp.0000263344.53000.a1","article-title":"Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.","volume":"83","author":"Thomas","year":"2007","journal-title":"Transplantation"},{"key":"R28-10-20260909","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/j.1600-6143.2008.02273.x","article-title":"Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial.","volume":"8","author":"Margreiter","year":"2008","journal-title":"Am J Transplant"},{"key":"R29-10-20260909","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/TP.0b013e3181b4acfb","article-title":"A randomized trial of alemtuzumab vs. antithymocyte globulin induction in renal and pancreas transplantation.","volume":"88","author":"Farney","year":"2009","journal-title":"Transplantation"},{"key":"R30-10-20260909","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","article-title":"for the INTAC Study Group. Alemtuzumab induction in renal transplantation.","volume":"364","author":"Hanaway","year":"2011","journal-title":"N Engl J Med"},{"key":"R31-10-20260909","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/TP.0b013e31822ca7ca","article-title":"Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapyan open label, randomized trial.","volume":"92","author":"Chan","year":"2011","journal-title":"Transplantation"},{"key":"R32-10-20260909","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1600-6143.2011.03891.x","article-title":"An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation.","volume":"12","author":"Cherukuri","year":"2012","journal-title":"Am J Transplant"},{"key":"R33-10-20260909","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/TP.0b013e318257ad41","article-title":"Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis.","volume":"93","author":"Morgan","year":"2012","journal-title":"Transplantation"},{"key":"R34-10-20260909","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/01.tp.0000281942.97406.89","article-title":"Alemtuzumab induction in deceased donor kidney transplantation.","volume":"84","author":"Huang","year":"2007","journal-title":"Transplantation"},{"key":"R35-10-20260909","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/TP.0b013e3181b724a5","article-title":"Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.","volume":"88","author":"Sampaio","year":"2009","journal-title":"Transplantation"},{"key":"R36-10-20260909","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.surg.2004.06.015","article-title":"Campath-1H in renal transplantation: The University of Wisconsin experience.","volume":"136","author":"Knechtle","year":"2004","journal-title":"Surgery"},{"key":"R37-10-20260909","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1111\/j.1600-6143.2005.01067.x","article-title":"Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab inductionlong-term results.","volume":"5","author":"Kaufman","year":"2005","journal-title":"Am J Transplant"},{"key":"R38-10-20260909","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jamcollsurg.2004.12.024","article-title":"Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or campath.","volume":"200","author":"Shapiro","year":"2005","journal-title":"J Am Coll Surg"},{"key":"R39-10-20260909","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/j.1600-6143.2005.00822.x","article-title":"Alemtuzumab (Campath-1H) induction therapy in cadaveric kidney transplantationefficacy and safety at five years.","volume":"5","author":"Watson","year":"2005","journal-title":"Am J Transplant"},{"key":"R40-10-20260909","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1097\/TP.0b013e31816f60cf","article-title":"Campath induction for kidney transplantation: report of 297 cases.","volume":"85","author":"Ortiz","year":"2008","journal-title":"Transplantation"},{"key":"R41-10-20260909","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1600-6143.2008.02492.x","article-title":"Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up.","volume":"9","author":"Tan","year":"2009","journal-title":"Am J Transplant"},{"key":"R42-10-20260909","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1034\/j.1600-6143.2003.00120.x","article-title":"Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.","volume":"3","author":"Knechtle","year":"2003","journal-title":"Am J Transplant"},{"key":"R43-10-20260909","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/01.TP.0000134398.86243.81","article-title":"Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction.","volume":"78","author":"Cai","year":"2004","journal-title":"Transplantation"},{"key":"R44-10-20260909","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1111\/j.1600-6143.2005.01123.x","article-title":"Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression.","volume":"5","author":"Flechner","year":"2005","journal-title":"Am J Transplant"},{"key":"R45-10-20260909","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1432-2277.2006.00388.x","article-title":"Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression after renal transplantation.","volume":"19","author":"Barth","year":"2006","journal-title":"Transplant Int"},{"key":"R47-10-20260909","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/j.1600-6143.2009.02581.x","article-title":"Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring.","volume":"9","author":"Knechtle","year":"2009","journal-title":"Am J Transplant"},{"key":"R48-10-20260909","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/TP.0b013e318222c9c6","article-title":"Antibody-mediated rejection after alemtuzumab induction: incidence, risk factors, and predictors of poor outcome.","volume":"92","author":"Willicombe","year":"2011","journal-title":"Transplantation"},{"key":"R49-10-20260909","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1432-2277.2012.01448.x","article-title":"Alemtuzumab as compared to alternative contemporary induction regimens.","volume":"25","author":"LaMattina","year":"2012","journal-title":"Transplant Int"},{"key":"R50-10-20260909","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1600-6143.2007.02134.x","article-title":"CD4CD25FOXP3 regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H.","volume":"8","author":"Bloom","year":"2008","journal-title":"Am J Transplant"},{"key":"R51-10-20260909","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/TP.0b013e318247a717","article-title":"Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation.","volume":"93","author":"Macedo","year":"2012","journal-title":"Transplantation"},{"key":"R52-10-20260909","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1034\/j.1600-6143.2002.020109.x","article-title":"Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.","volume":"2","author":"Lebranchu","year":"2002","journal-title":"Am J Transplant"},{"key":"R53-10-20260909","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/01.TP.0000129812.68794.CC","article-title":"Sequential protocols using basiliximab versus anti-thymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids.","volume":"78","author":"Mourad","year":"2004","journal-title":"Transplantation"},{"key":"R54-10-20260909","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1097\/TP.0b013e3181d02496","article-title":"Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.","volume":"89","author":"Kandus","year":"2010","journal-title":"Transplantation"},{"key":"R55-10-20260909","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"for the Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.","volume":"355","author":"Brennan","year":"2006","journal-title":"N Engl J Med"},{"key":"R56-10-20260909","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000101290.20629.DC","article-title":"A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.","volume":"77","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"key":"R57-10-20260909","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/01.TP.0000101495.22734.07","article-title":"A randomized long-term trial of tacrolimussirolimus versus tacrolimusmycophenolate mofetil versus cyclosporine (NEORAL)sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year.","volume":"77","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"key":"R58-10-20260909","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/ki.1993.259","article-title":"International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology.","volume":"44","author":"Solez","year":"1993","journal-title":"Kidney Int"},{"key":"R59-10-20260909","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1600-6143.2006.01688.x","article-title":"Banff 05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN).","volume":"7","author":"Solez","year":"2007","journal-title":"Am J Transplant"},{"key":"R60-10-20260909","first-page":"31","article-title":"Prediction of creatinine clearance from serum creatinine.","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00007890-201406150-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:18:57Z","timestamp":1788963537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-201406150-00010"}},"subtitle":["Long-Term Results"],"short-title":[],"issued":{"date-parts":[[2014,6,15]]},"references-count":59,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/01.tp.0000441089.39840.66","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,15]]}}}